Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Droessler

Physical Medicine & Rehabilitation Santa Monica, CA Medical Doctor

NPI 1821594540 CMS profile 7229455

1131 Wilshire Blvd Ste 100, Ste 100, Santa Monica, CA 90401

Open in the dashboard

General payments

$34,735

309 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Droessler of Santa Monica, CA is reported in the CMS Open Payments database as having received $34,735 across 309 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,481 108
2024 General $8,320 90
2023 General $5,773 72
2022 General $10,642 34
2021 General $246 3
2020 General $150 1
2019 General $124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Droessler
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jonathan Droessler were reported at $9,481. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jonathan Droessler Physical Medicine & Rehabilitation median Middle half National median
2019 $124 $133 $45–$390 $163
2020 $150 $88 $29–$272 $114
2021 $246 $116 $33–$360 $132
2022 $10,642 $123 $40–$378 $149
2023 $5,773 $131 $43–$396 $160
2024 $8,320 $141 $45–$409 $164
2025 $9,481 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $18,555 131 payments
  2. Boston Scientific Corporation $6,954 93 payments
  3. SPR Therapeutics, Inc $3,640 32 payments
  4. Globus Medical, Inc. $757 7 payments
  5. Stryker Corporation $741 5 payments
  6. Nevro Corp. $697 6 payments
  7. Abbott Laboratories $697 7 payments
  8. Nalu Medical, Inc. $617 8 payments
  9. Vertos Medical, Inc. $372 4 payments
  10. Ipsen Biopharmaceuticals, Inc $264 2 payments
  11. Other $1,440 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,239 273 payments
  2. Grant $7,500 1 payment
  3. Travel and Lodging $5,995 35 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $7,500 96 payments
  2. SYNCHROMEDII $7,500 1 payment
  3. SPRINT PNS System $3,640 32 payments
  4. VANTA ADAPTIVESTIM $1,777 14 payments
  5. KYPHON EXPRESS II KYPHOPAK TRAY $1,569 17 payments
  6. General - Pain Management $1,273 16 payments
  7. WaveWriter Alpha Prime 16 $1,220 21 payments
  8. Superion Indirect Decompression System $778 9 payments
  9. Senza $757 7 payments
  10. Intracept $738 8 payments
  11. Other $6,615 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

67

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$804

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

16.4%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calcitonin-Salmon Calcitonin,salmon,synthetic Brand 11 $517
Meloxicam Generic 29 $148
Gabapentin Generic 27 $139

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$54,691

Medicare's payments for the services billed

Medicare patients

268

Average age 76

Services billed

572

155 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 44%
Osteoporosis 34%
Depression 33%
Diabetes 31%
Chronic kidney disease 30%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

309 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record